ASCO: Impact of 2 New Drugs for the Treatment of Metastatic Melanoma

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Dr. Antoni Ribas, UCLA’s Jonsson Comprehensive Cancer Center and a presenter at this year’s annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.

Dr. Antoni Ribas, UCLA's Jonsson Comprehensive Cancer Center and a presenter at this year's annual meeting of the American Society of Clinical Oncology, discusses the impact of 2 new drugs- ipilimumab (Yervoy) and vemurafenib (Zelboraf)-for the treatment of metastatic melanoma.

Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Related Content
Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.

FDA Approves Cosibelimab in Cutaneous Squamous Cell Carcinoma

Tim Cortese
December 13th 2024
Article

Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma

IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma

Russ Conroy
November 8th 2024
Article

Phase 1 data highlight a manageable safety profile with IMA203 among patients with melanoma and other PRAME-positive solid tumors.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

Ritu Salani, MD;Tanios S. Bekaii-Saab, MD, FACP
June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.

PRAME-Targeted Agent Shows Activity in Pretreated Metastatic Melanoma

Russ Conroy
October 14th 2024
Article

Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.

The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.

Fianlimab Combo Shows Activity in Advanced Melanoma Subtypes

Jax DiEugenio
October 14th 2024
Article

The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.